These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
675 related articles for article (PubMed ID: 28322067)
1. The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection. Özdener AE; Park TE; Kalabalik J; Gupta R Expert Rev Anti Infect Ther; 2017 May; 15(5):467-481. PubMed ID: 28322067 [TBL] [Abstract][Full Text] [Related]
2. Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection. Trang TP; Dong BJ; Kojima N; Klausner JD Expert Opin Drug Saf; 2016 Sep; 15(9):1287-94. PubMed ID: 27391203 [TBL] [Abstract][Full Text] [Related]
3. Antiretroviral agents in pre-exposure prophylaxis: emerging and advanced trends in HIV prevention. Yap PK; Loo Xin GL; Tan YY; Chellian J; Gupta G; Liew YK; Collet T; Dua K; Chellappan DK J Pharm Pharmacol; 2019 Sep; 71(9):1339-1352. PubMed ID: 31144296 [TBL] [Abstract][Full Text] [Related]
4. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States. Adams JL; Shelley K; Nicol MR Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960 [TBL] [Abstract][Full Text] [Related]
5. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges. Krakower DS; Mayer KH Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022 [TBL] [Abstract][Full Text] [Related]
6. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis? Parikh UM; Mellors JW Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640 [TBL] [Abstract][Full Text] [Related]
7. Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention. Mugwanya KK; Baeten JM Expert Opin Drug Saf; 2016; 15(2):265-73. PubMed ID: 26634852 [TBL] [Abstract][Full Text] [Related]
8. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. Myers GM; Mayer KH AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497 [TBL] [Abstract][Full Text] [Related]
9. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE. Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I; BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719 [TBL] [Abstract][Full Text] [Related]
10. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP). Wang H; Zhang Y; Mei Z; Jia Y; Leuba SI; Zhang J; Chu Z; Ding H; Jiang Y; Geng W; Shang H; Xu J BMC Infect Dis; 2019 Aug; 19(1):721. PubMed ID: 31416439 [TBL] [Abstract][Full Text] [Related]
11. Short Communication: Tenofovir Disoproxil Fumarate/Emtricitabine Fits for All as Appropriate HIV-1 Pre-Exposure Prophylaxis? Taramasso L; Riccardi N; Del Puente F; Bruzzone B; Ripamonti D; D'Ambrosio B; Viscoli C; Di Biagio A AIDS Res Hum Retroviruses; 2018 Feb; 34(2):168-170. PubMed ID: 29166777 [TBL] [Abstract][Full Text] [Related]
12. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes. Wang X; Nwokolo N; Korologou-Linden R; Hill A; Whitlock G; Day-Weber I; McClure MO; Boffito M HIV Med; 2018 Jan; 19(1):1-6. PubMed ID: 28657199 [TBL] [Abstract][Full Text] [Related]
14. An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate. Baum MM; Butkyavichene I; Churchman SA; Lopez G; Miller CS; Smith TJ; Moss JA Int J Pharm; 2015 Nov; 495(1):579-587. PubMed ID: 26386138 [TBL] [Abstract][Full Text] [Related]
15. Mathematical Modelling of the Molecular Mechanisms of Interaction of Tenofovir with Emtricitabine against HIV. Iannuzzi S; von Kleist M Viruses; 2021 Jul; 13(7):. PubMed ID: 34372560 [TBL] [Abstract][Full Text] [Related]
16. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017. Sullivan PS; Giler RM; Mouhanna F; Pembleton ES; Guest JL; Jones J; Castel AD; Yeung H; Kramer M; McCallister S; Siegler AJ Ann Epidemiol; 2018 Dec; 28(12):833-840. PubMed ID: 30037634 [TBL] [Abstract][Full Text] [Related]
17. Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women. Mugwanya KK; John-Stewart G; Baeten J Expert Opin Drug Saf; 2017 Jul; 16(7):867-871. PubMed ID: 28571500 [TBL] [Abstract][Full Text] [Related]
18. Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns. Tetteh RA; Yankey BA; Nartey ET; Lartey M; Leufkens HG; Dodoo AN Drug Saf; 2017 Apr; 40(4):273-283. PubMed ID: 28130774 [TBL] [Abstract][Full Text] [Related]
19. Updating the Adherence-Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender Women. Anderson PL; Marzinke MA; Glidden DV Clin Infect Dis; 2023 May; 76(10):1850-1853. PubMed ID: 36645796 [TBL] [Abstract][Full Text] [Related]
20. Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force. Chou R; Evans C; Hoverman A; Sun C; Dana T; Bougatsos C; Grusing S; Korthuis PT JAMA; 2019 Jun; 321(22):2214-2230. PubMed ID: 31184746 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]